前列腺癌与伴不同合并症的良性前列腺增生患者血清前列腺特异性抗原的比较

摘要

Objective To analyze the difference of serum prostate specific antigen between prostate cancer and benign prostatic hyperplasia complicated with different complications,in order to diagnose the disease.Methods 32 patients with pros-tate cancer and 115 cases of benign prostatic hyperplasia were selected.Prostate specific antigen ( PSA) was detected by radioim-munoassay,the total PSA (TPSA) differences and TPSA and free PSA (FPSA) ratio of different groups were analyzed.Results TPSA of prostate cancer patients was (61.2 ±27.5) μg/L,FPSA/TPSA was (0.14 ±0.03);TPSA of patients with BPH and a-cute urinary retention was (5.2 ±2.5) μg/L,FPSA/TPSA was (0.26 ±0.05);TPSA of patients with BPH and urinary tract in-fection was (6.8 ±2.1) μg/L,FPSA/TPSA was (0.24 ±0.06);TPSA of patients with BPH merger prostatitis was (8.3 ±5.4)μg/L,FPSA/TPSA was (0.22 ±0.06);TPSA of patients with BPH without complications was (2.9 ±0.5) μg/L,FPSA /TPSA was (0.27 ±0.05).TPSA of patients with prostate cancer was significantly higher than benign prostatic hyperplasia comorbidity group,FPSA/TPSA ratio is less than benign prostatic hyperplasia group,the difference was statistically significant (P<0.05). Conclusion TPSA and FPSA/TPSA is instructive in the clinical diagnosis and differential diagnosis of prostate cancer.%目的：探讨前列腺癌与伴不同合并症的良性前列腺增生患者血清前列腺特异性抗原间的差异，从而更好地对疾病进行诊断。方法选取前列腺癌患者32例和良性前列腺增生患者115例。采用放射免疫法对患者血清前列腺特异性抗原（ PSA）进行检测，分析不同组间总PSA（ TPSA）的差异以及TPSA与游离PSA（ FPSA）的比值。结果前列腺癌患者TPSA为（61．2±27．5）μg／L，FPSA／TPSA为（0．14±0．03）；BPH合并急性尿潴留组患者TPSA为（5．2±2．5）μg／L，FPSA／TPSA为（0．26±0．05）；BPH合并尿路感染组患者TPSA为（6．8±2．1）μg／L，FPSA／TPSA为（0．24±0．06）；BPH合并前列腺炎患者TPSA为（8．3±5．4）μg／L，FPSA／TPSA为（0．22±0．06）；BPH无合并症组患者TPSA为（2．9±0．5）μg／L，FPSA／TPSA为（0．27±0．05）。前列腺癌患者TPSA明显高于良性前列腺增生合并症组，FPSA／TPSA比值低于前列腺增生组，差异具有统计学意义（P＜0．05）。结论 TPSA以及FPSA／TPSA在临床上对于前列腺癌的诊断及鉴别诊断有指导意义。